| Entries |
| Document | Title | Date |
|---|
| 20080199402 | Contrast Agents - The present invention relates to iodine containing compounds containing a central cyclopropane scaffolding moiety allowing for the arrangement of three iodinated phenyl groups bound thereto. | 08-21-2008 |
| 20080206147 | Method for the Use of [11C]Carbon Monoxide in Labeling Synthesis of 11C-Labelled Acids by Photo-Induced Free Radical Carbonylation Under Mild Conditions Using Sulfoxides - Methods and reagents for photo-initiated carbonylation with carbon-isotope labeled carbon monoxide using alkyl/aryl iodides with sulfoxides and triethylamine are provided. The resultant carbon-isotope labeled acids, and pharmaceutical acceptable salts and solvates are useful as radiopharmaceuticals, especially for use in Positron Emission Tomography (PET). Associated kits and method for PET studies are also provided. | 08-28-2008 |
| 20080233049 | Agents And Methods For Early Diagnosis And Monitoring Of Alzheimer's Disease And Other Neurological Disorders - This invention is in the fields of medicine and neurology, and relates to methods and agents for early diagnosis and monitoring of Alzheimer's disease and other neurological disorders. More particularly, the present invention provides the method for evaluating the health of central nervous system neurons in a human patient, comprising the steps of: a) administering to said patient a population of molecular complexes comprising (i) a polypeptide capable of activating neuronal endocytosis, axonal transport, and synaptic transfer; and (ii) an imaging agent suited for determining location and evaluating neuronal transport of said molecular complexes within said patient; and b) using at least one imaging method to determine location and evaluate neuronal transport of said molecular complexes within said patient. | 09-25-2008 |
| 20080267881 | IMAGING AGENTS - The invention relates to compounds of formula (I): and their use as targeting vectors that bind to receptors associated with angiogenesis. Such compounds may thus be used for diagnosis or therapy of, for example, malignant diseases, heart diseases, endometriosis, inflammation-related diseases, rheumatoid arthritis and Kaposi's sarcoma. | 10-30-2008 |
| 20080267882 | Imaging compounds, methods of making imaging compounds, methods of imaging, therapeutic compounds, methods of making therapeutic compounds, and methods of therapy - Embodiments of the present disclosure provide for RGD compounds that include a multimeric RGD (arginine-glycine-aspartic acid (Arg-Gly-Asp)) peptide, methods of making the RGD compound, pharmaceutical compositions including RGD compound, methods of using the RGD compositions or the pharmaceutical compositions including RGD compositions, methods of diagnosing and/or targeting angiogenesis related disease and related biological events, kits for diagnosing and/or targeting angiogenesis related disease and related biological events, and the like. In addition, the present disclosure includes compositions used in and methods relating to non-invasive imaging (e.g., positron emission tomography (PET) imaging) of the RGD compounds in vivo. | 10-30-2008 |
| 20080279779 | CT tomographic imaging process and system - A CT radiographic imaging process implements a processing operation on images in order to detect the use of a saline solution. When a saline solution is detected, it extracts a component or a portion of a component that does not appear to be contrasted in the initial images, for example, in the case of cardiac imaging, the right cavity of the heart. The imaging system comprises means for implementing this process. | 11-13-2008 |
| 20080317673 | METHOD FOR DIAGNOSING AND TREATING BRONCHIAL ASTHMA - A method for diagnosing and treating a bronchial asthma by classifying a patient's asthma as Type I, Type II or Type III based on the patient's symptoms is disclosed. The symptoms for the three types of asthma are disclosed together with recommended treatment guidelines for each type to optimize treatment regiments based on symptoms. | 12-25-2008 |
| 20090047218 | Method for producing albumin conjugates comprising an X-ray contrast medium as the active substance - The invention concerns X-ray contrast medium-protein conjugates and in particular X-ray contrast medium-albumin conjugates, medicaments comprising X-ray contrast medium-protein conjugates, processes for the production of such conjugates as well as the use thereof. | 02-19-2009 |
| 20090191128 | CORE-SHELL NANOPARTICLES FOR THEARAPY AND IMAGING PURPOSES - The invention relates to nanoparticles coated with an inorganic nanoscale material herein referred to as core-shell nanoparticle, in which the core material has a wider band gap than the shell material. The described core-shell nanoparticles are very suitable for the application in photodynamic therapy due to their enhanced energy transfer ability. | 07-30-2009 |
| 20090202441 | COMPOSITIONS AND METHODS TO PREVENT CANCER WITH CUPREDOXINS - The present invention discloses methods and materials for killing and/or inhibiting the growth of a cancer cell via preferential entry of a cytotoxic compound. Preferential entry of the cytotoxic compound is accomplished by the use of protein transduction domains derived from cupredoxins, including the p18 and p28 truncations of azurin. | 08-13-2009 |
| 20090208417 | Detection and Localized Imaging of Cancer Using X-Ray Fluorescent Nanoparticle/Preferential Locator Conjugates - A method for detecting gold or other nanoparticles conjugated to preferential locators commences by contacting tissue suspected of being neoplastic with gold nanoparticle/preferential locator conjugates for a time adequate for the conjugates to bind with the tissue. A beam of gamma photons (such as from, | 08-20-2009 |
| 20090246141 | HIGHER FATTY ACID TRIESTER AND AMIDE DERIVATIVE HAVING DIETHYLENETRIAMINE-TYPE METAL CHELATE STRUCTURE - A compound having superior solubility and suitable for a liposome contrast medium selective for a lesion such as vascular diseases is provided which is represented by the following general formula (I) wherein R | 10-01-2009 |
| 20090246142 | Triggered Self-Assembly of Nanoparticles In Vivo - The present invention provides triggered self-assembly nanosystems. Such nanosystems comprise a population of triggered self-assembly conjugates, each conjugate comprising one or more monomeric units and one or more complementary binding moieties. In some embodiments, inventive nanosystems and conjugates can be used to treat and/or diagnose a disease, disorder, and/or condition. | 10-01-2009 |
| 20090311192 | CORE AND CORE-SHELL NANOPARTICLES CONTAINING IODINE FOR X-RAY IMAGING - Nanoparticles having an average particle size of less than 2000 nm, wherein said nanoparticles comprise a polymer having pendant cleavable iodine substituted groups are provided. Processes for preparing the nanoparticles and their use as a contrast agent for X-ray imaging are also described. | 12-17-2009 |
| 20100021389 | RADIOGRAPHIC CONTRAST AGENT FOR POSTMORTEM, EXPERIMENTAL AND DIAGNOSTIC ANGIOGRAPHY - A contrast agent for angiography is disclosed, in particular, for examining animal or human bodies or components thereof such as members or organs thereof, comprising an essentially oil-based apolar contrast component for X-ray examinations, the contrast component having a contrast component viscosity in the range of 30-100 mPas. The contrast agent is characterised in that the contrast component is present in a mixture with at least one further apolar component, the viscosity of which is less than or at most equal to the contrast component viscosity. Methods for angiography examination are also disclosed, in which such a contrast agent or also a polar contrast agent are used at least periodically and applications of such contrast agents. | 01-28-2010 |
| 20100028264 | LTBP2 AS A BIOMARKER, THERAPEUTIC AND DIAGNOSTIC TARGET - The invention provides LTBP2, which is associated with cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of LTBP2 as well as pharmaceutical compositions comprising such compounds. The invention also provides LTBP2 as a biomarker for diseases such as cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. | 02-04-2010 |
| 20100086489 | OSTEOPENIA ANIMAL MODEL - The present invention provides a method for producing an osteopenia animal model by RANKL administration and an osteopenia animal model. | 04-08-2010 |
| 20100092392 | Pet Scanning Determination of Lymph Nodes Enriched in 124 I Labeled Antibodies for Cancer Patient Prognostication - A method for detecting antigen associated with adenocarcinoma commences by forming a | 04-15-2010 |
| 20100158811 | ASSESSING BRAIN ANEURYSMS - This document provides methods and materials related to assessing brain conditions within mammals. For example, methods and materials that can be used to determine whether or not a mammal (e.g., a human) with a brain aneurysm is likely to experience brain aneurysm rupture are provided. | 06-24-2010 |
| 20100189656 | CONTRAST AGENTS - The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds. More specifically the iodine containing compounds are chemical compounds containing a triamine alkyl central moiety allowing for the arrangement of three iodinated phenyl groups bound thereto. The invention also relates to the use of such diagnostic compositions as contrast agents in diagnostic imaging and in particular in X-ray imaging and to contrast media containing such compounds. | 07-29-2010 |
| 20100272649 | Bioactive Bone Cement and Method for Its Production - A bioactive PMMA (polymethylmethacrylate) bone cement contains a powder component and a reactive monomer liquid, wherein the powder component and the reactive monomer liquid when mixed with one another react with one another and form a polymer-based solid material. The powder component contains particulate polymer powder of polymethylmethacrylates; a radical starter; and anionic copolymer nanoparticles. The anionic copolymer nanoparticles are distributed in nano-particulate form within the particulate powder component or coated as a film on particles of the particulate polymer powder. | 10-28-2010 |
| 20110020237 | Compositions and Methods for Inhibiting Drusen Formation and for Diagnosing or Treating Drusen-Related Disorders - Compositions of matter and methods for inhibiting drusen or drusen-like deposits and/or for treating diseases related to drusen or drusen-like deposits in human or animal subjects by administering to the subject a therapeutically effective amount of i) a conformational epitope of an aggregate that contributes to the formation or biosynthesis of drusen or drusen-like deposits and/or ii) an antibody that binds to a conformational epitope of an aggregate that contributes to the formation or biosynthesis of drusen or the drusen-like deposit. | 01-27-2011 |
| 20110020238 | STABILIZING AQUEOUS SOLUTION OF IODINE CHLORIDE BY ADDING SODIUM CHLORIDE - This invention relates generally to non-ionic X-ray contrast agents. It further relates to the preparation of iodine chloride, a key reagent in the synthesis of non-ionic X-ray contrast agents such as iodixanol and iohexol. In particular, the iodine chloride is produced in a reaction involving iodine, sodium chlorate, and hydrochloric acid as the starting materials. The instant invention relates to a method of stabilizing aqueous iodine chloride solutions by adding about one to about four molar equivalents of sodium chloride relative to sodium chlorate to an aqueous reaction mixture of sodium chlorate, hydrochloric acid, and iodine. | 01-27-2011 |
| 20110052503 | BIODEGRADABLE CONTRAST AGENTS - The present invention provides a radio-opaque composition comprising a cleavable, preferably enzymatically-cleavable, derivative of a physiologically tolerable organoiodine compound and a non-acrylic polymer wherein said derivative is incorporated in said non-acrylic polymer. | 03-03-2011 |
| 20120003159 | COMPOSITIONS AND METHODS FOR ENHANCING CONTRAST IN IMAGING - Examples of compositions of liposomes and methods of making the same containing high concentrations of contrast-enhancing agents for computed tomography are provided. Example compositions of such liposomes, when administered to a subject, provide for increased contrast of extended duration, as measured by computed tomography, in the bloodstream and other tissues of the subject. Also provided are example methods for making the liposomes stable, that is, resistant to leakage of the contrast-enhancing agents, including the extrusion of the liposomes at high pressures and at high flow rates per total pore area of the extrusion filters. | 01-05-2012 |
| 20120027687 | FATTY ACID PROTEIN KINASE C ACTIVATORS AND ANTICOAGULANT FOR THE TREATMENT OF STROKE - The present disclosure provides a method for treating stroke by administering an anticoagulant, e.g., recombinant tissue plasminogen activator (rTPA), and a protein kinase C(PKC) activator, wherein the PKC activator may be administered before, after, or at the same time as the rTPA. The methods disclosed herein may limit the size of infarction and/or reduce mortality, the disruption of the blood-brain barrier, and/or the hemorrhagic damage due to ischemic stroke compared with rTPA administration alone; and may also extend the therapeutic time window for administering rTPA after a stroke. Also disclosed are compositions and kits comprising rTPA and a PKC activator for treating stroke. | 02-02-2012 |
| 20120076734 | RADIOPAQUE ANTIBIOTIC DENTAL PASTE AND USES THEREOF - Compositions useful for disinfecting a dental wound are described. The compositions include an active ingredient comprising one or more antibiotics, a radiopaque substance, and optionally a pharmaceutically acceptable excipient. Methods for treating dental wound sites with the compositions are also described. | 03-29-2012 |
| 20120328528 | MONOCLONAL ANTIBODY AGAINST NECROSIS MARKER PRDX4 AND USE THEREOF - [PROBLEM] To provide a monoclonal antibody against a biomarker which shows high specificity and can be effectively used in detection and diagnosis of various lesions relevant to various kinds of carcinomas and foci of necrosis, and so forth. | 12-27-2012 |
| 20130004428 | DIAZABICYCLONONYL OXADIAZOLE COMPOUNDS AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS - This invention relates to diazabicyclononyl oxadiazolyl derivatives, which are found to-be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances. Ar | 01-03-2013 |
| 20130071332 | LABELED MOLECULAR IMAGING AGENTS AND METHODS OF USE - Imaging agents are described that comprise labeled substrates capable of being introduced into cells via the cystine/glutamate antiporter. The substrates may be used for imaging or detecting oxidative stress in cells by introducing the labeled agents into cells via the cystine/glutamate antiporter and subsequent detection. | 03-21-2013 |
| 20130071333 | METHOD AND SYSTEM FOR IDENTIFYING, ASSESSING, AND MANAGING CANCER GROWTH RATES AND POTENTIAL METASTASIS - Techniques described herein generally relate to identifying, assessing, and managing cancer growth rates and potential metastasis. Some example methods may include constructing one or more quantitative metrics for the potential metastasis in a selected population of other patients, acquiring a first set of numeric biomarker data for the patient before having placed a biomarker in the patient, acquiring a second set of numeric biomarker data for the patient after having placed the biomarker in the patient, determining a set of biomarker surrogate values for microvessel density information based on a mean numeric biomarker difference derived from the first set of numeric biomarker data and the second set of numeric biomarker data, determining a set of biomarker surrogate values for microvessel density information based on a mean numeric biomarker difference derived from the first set of numeric biomarker data and the second set of numeric biomarker data, and predicting quantitative and objective risk for the cancer growth rates and potential metastasis and adjusting a treatment plan based on the biomarker surrogate values and at least one of the one or more quantitative metrics. | 03-21-2013 |
| 20130071334 | METHOD AND SYSTEM FOR IDENTIFYING, ASSESSING, AND MANAGING CANCER DISEASE - Techniques described herein generally relate to identifying, assessing, and managing cancer diseases. Some example methods may include constructing one or more quantitative metrics for the cancer disease in a selected population of other patients retrieved during the scheduling interval, acquiring a first set of numeric biomarker data for the patient before having placed a biomarker in the patient, acquiring a second set of numeric biomarker data for the patient after having placed the biomarker in the patient, identifying one or more nodules from the first set of numeric biomarker data and the second set of numeric biomarker data, wherein each of the one or more nodules is characterized by a mean numeric biomarker difference value derived from the first set of numeric biomarker data and the second set of numeric biomarker data, and predicting quantitative and objective risk for the one or more nodules based on the mean numeric biomarker difference value and at least one of the one or more quantitative metrics. | 03-21-2013 |
| 20130202535 | X-RAY VISIBLE MEDICAL DEVICE AND PREPARATION METHOD THEREOF - The present invention relates to an X-ray visible medical device comprising a medical device and a layer bound onto the medical device, wherein the layer is composed of an X-ray contrast material or a composite of the X-ray contrast material and a biocompatible polymer. Also disclosed is a method for preparing the X-ray visible medical device. | 08-08-2013 |
| 20130287697 | Pharmaceutical microsphere for embolization - A pharmaceutical microparticle for embolization is disclosed, which includes: a thermoresponsive polymer, an enhancer, a contrast agent, and a solvent. The particle size of pharmaceutical microparticle for embolization is 100-750 μm. The pharmaceutical microparticle for embolization of the present invention is an effective drug carrier, and has biodegradable and X-ray imaging properties. | 10-31-2013 |
| 20130287698 | TREATMENT OF RENAL HYPERTENSION OR CAROTID SINUS SYNDROME WITH ADVENTITIAL PHARMACEUTICAL SYMPATHETIC DENERVATION OR NEUROMODULATION - Sympathetic nerves run through the adventitia surrounding renal arteries and are critical in the modulation of systemic hypertension. Hyperactivity of these nerves can cause renal hypertension, a disease prevalent in 30-40% of the adult population. Hypertension can be treated with neuromodulating agents (such as angiotensin converting enzyme inhibitors, angiotensin II inhibitors, or aldosterone receptor blockers), but requires adherence to strict medication regimens and often does not reach target blood pressure threshold to reduce risk of major cardiovascular events. A minimally invasive solution is presented here to reduce the activity of the sympathetic nerves surrounding the renal artery by locally delivering neurotoxic or nerve-blocking agents into the adventitia. Extended elution of these agents may also be accomplished in order to tailor the therapy to the patient. | 10-31-2013 |
| 20130295018 | LIQUID PREPARATION FOR ORAL ADMINISTRATION USED FOR CT COLONOGRAPHY AND COMPOSITION FOR GASTROINTESTINAL RADIOGRAPHY - The present invention provides a liquid preparation for oral administration that is capable of reducing the amount of colonic irrigation solution taken during gastrointestinal pretreatment and decreasing the burden on the subject without sacrificing test accuracy and without prolonging the time required for pretreatment, and a composition for gastrointestinal radiography used to prepare the liquid preparation for oral administration. Namely, provided are a liquid preparation for oral administration taken during gastrointestinal imaging by CT colonography that comprises an iodine compound and a water-soluble polymer or saline laxative, wherein 300 mL to 1200 mL are taken on the day before CT colonography in a single administration or divided among several administrations, and a composition for gastrointestinal radiography comprising an iodine compound and a water-soluble polymer or saline laxative, wherein 300 mL to 1200 mL are taken in the form of an aqueous solution, having an iodine content of 3.5 mg/mL to 90 mg/mL prepared by dissolving in water, on the day before CT colonography in a single administration or divided among several administrations. | 11-07-2013 |
| 20130336893 | Exedin-4 Peptide Analogues - The present invention relates to exendin-4 peptide analogues and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake. | 12-19-2013 |
| 20130336894 | ONCOFETAL ANTIGEN/IMMATURE LAMININ RECEPTOR ANTIBODIES FOR DIAGNOSTIC AND CLINICAL APPLICATIONS - The present invention relates to antibodies against Oncofetal Antigen/immature Laminin receptor protein (OFA/iLRP) that can be used singly or in conjunction to detect or treat OFA/iLRP-related diseases. More specifically, the antibodies can be used for several purposes including: (i) detecting and measuring OFA/iLRP in different biofluids; and (ii) using OFA/iLRP with an antibody directed against the monomeric form and its associated diseases. | 12-19-2013 |
| 20140037552 | PRUSSIAN BLUE BASED NANOPARTICLE AS MULTIMODAL IMAGING CONTRAST MATERIAL - The invention relates to a Prussian Blue based nanoparticle comprising a Prussian Blue based metal core doped with one or more metal isotope and an organic biocompatible coating. The invention relates furthermore to a process for the preparation of said nanoparticle, and the use thereof as imaging contrast material or in the therapy. | 02-06-2014 |
| 20140056816 | IMPLANTS AND BIODEGRADABLE FIDUCIAL MARKERS - Implantable materials may be used in an iatrogenic site. Applications include radioopaque materials for fiducial marking. Applications include a method of treating a patient with a pharmaceutically acceptable implant system comprising implanting a collection of pharmaceutically acceptable, covalently-crosslinked hydrogel particles, wherein the collection comprises a plurality of sets of the particles, with the sets having different rates of biodegradation. | 02-27-2014 |
| 20140065074 | METHOD OF TRACKING GROWTH AND METASTASIS OF SPECIFIC CELLS IN VIVO - A method of tracking growth and metastasis of specific cells in vivo is disclosed. The method of the disclosure includes culturing the specific cells in a medium containing 0.1 μM to 10 mM nanoparticles as a biomarker for X-rays, such that the specific cells carry the nanoparticles, administering the specific cells carrying the nanoparticles to a subject, irradiating the subject by an X-ray source, and determining the growth and metastasis of the specific cells by X-ray images of the nanoparticles in the subject. | 03-06-2014 |
| 20140072514 | POLYTETRAFLUOROETHYLENE CO-POLYMER EMULSIONS - The present disclosure is directed to a class of fluorinated copolymers, such as PTFE copolymers, that can be dissolved in low toxicity solvents, such as Class III Solvents, and that enable the creation of stable water-in-solvent emulsions comprising the fluorinated copolymers dissolved in a low toxicity solvents and a hydrophilic agent (e.g., a therapeutic agent) dissolved in an aqueous solvent, such as water or saline. | 03-13-2014 |
| 20140161725 | Molecular Imaging of Cancer Cells In Vivo - Cellular targets on cancer cells have been identified that can be used with targeted molecular imaging to detect the cancer cells in vivo. Non-invasive methods for detecting cancer cells, such as metastasized cancer cells, are therefore provided. Also provided are compositions and kits for use in the disclosed methods. | 06-12-2014 |
| 20140219922 | Use of scintillator-based nanoparticles for in vivo control of light-sensitive bioactive molecules - The method for remote, non-invasive in vivo control of the activation of light-sensitive bioactive molecules for the purpose of research or therapy is based on delivering to the required site of the body of nanoparticles along with said light-sensitive bioactive molecules. Nanoparticles' core is made from scintillator material that absorbs X-ray and in response emits visible light; they have biocompatible protective coating and surface targeting agents enabling accumulation at the required site(s) within the body. Irradiation of the site with the highly penetrable X-rays causes nanoparticles to emit visible light which will activate light-sensitive bioactive molecule(s) within this site inducing sought therapeutic effect. | 08-07-2014 |
| 20140219923 | BIODEGRADABLE COMPOSITIONS SUITABLE FOR CONTROLLED RELEASE - A special class of drug-depot forming triblock copolymers which are very suitable for the loading, containment and releasing of sensitive drugs such as proteins from biodegradable, injectable drug depots. How to visualize these depots for various imaging related purposes is described. A composition comprising a tri-block copolymer according to formula 1 B-A-B ( | 08-07-2014 |
| 20140219924 | MEDICAL TISSUE-MARKER AND MANUFACTURING METHOD FOR THE SAME - The present invention is to provide a medical tissue-marker which enables the identification of a location even from the outside of an organ, can remain topical over a long period, and enables the easy identification of a marked location within the whole organ; also to provide a manufacturing method for the medical tissue-marker. The medical tissue-marker as in the present invention includes a vesicle formed by the synthesis of a phospholipid and a near infrared fluorescent dye, and an emulsion formed by the synthesis of the phospholipid and an X-ray contrast medium, and has agglomerated clusters wherein the vesicle and the emulsion are contained in a hydrophilic solvent and a plurality of capsules are formed by means of an emulsifier. | 08-07-2014 |
| 20140322138 | METHOD OF RELIABLE PARTICLE SIZE CONTROL FOR PREPARING AQUEOUS SUSPENSION OF PRECIOUS METAL NANOPARTICLES AND THE PRECIOUS METAL NANOPARTICLE SUSPENSION PREPARED BY THE METHOD THEREOF - Disclosed is a method for making a colloidal suspension of precious metal nanoparticles. The method comprises providing a target material comprising a precious metal in a liquid dispersion medium in an ablation container. The dispersion medium has an electrical conductivity within a predetermined conductivity range. Laser pulses are used to generate the nanoparticles from the target in the container. While generating the nanoparticles the electrical conductivity of the dispersion medium is monitored and maintained within the predetermined range and thereby the generated nanoparticles are produced within a predetermined size range. The generated nanoparticles are used to form a colloidal suspension. | 10-30-2014 |
| 20150118160 | RADIOPAQUE BONE REPAIR MIXTURE AND METHOD OF USE - A composition of a bone repair mixture has a quantity of allograft particulate bone having a bone particle distribution of particle sizes less than 700 micron and a quantity of biologic carrier material intermixed with the particulate bone. The biologic carrier material is one of fascia, deep fascia or a fascia mixture. Preferably, the carrier material is exclusively fascia lata. | 04-30-2015 |
| 20150139911 | PREVENTION OF MYOCARDIAL INFARCTION INDUCED VENTRICULAR EXPANSION AND REMODELING - A method for direct therapeutic treatment of myocardial tissue in a localized region of a heart having a pathological condition. The method includes identifying a target region of the myocardium and applying material directly and substantially only to at least a portion of the myocardial tissue of the target region. The material applied results in a physically modification the mechanical properties, including stiffness, of said tissue. Various devices and modes of practicing the method are disclosed for stiffening, restraining and constraining myocardial tissue for the treatment of conditions including myocardial infarction or mitral valve regurgitation. | 05-21-2015 |
| 20150353631 | C-TERMINAL AND CENTRAL EPITOPE A-BETA ANTIBODIES - The present invention provides antibodies directed against C-terminal and central epitopes of Aβ that preferentially bind compact plaques relative to diffuse plaques. The invention also provides methods of treating patients to reduce or eliminate the presence of compact plaques of Aβ and associated symptoms. | 12-10-2015 |
| 20150374883 | Bone Graft Substitute Containing a Temporary Contrast Agent and a Method of Generating Such and A Method of Use Thereof - A bone graft substitute for use in orthopedic bone grafting procedures comprising a radiolucent bone graft substitute combined with a temporary radiopaque agent. Methods of making and using the composition are also disclosed. Bone graft substitutes have become an effective means of regenerating bone in orthopedic procedures where bone loss results from surgically created defects or traumatic injury to the bone. Bone graft substitutes include mineral-based materials such as hydroxyapatite, calcium phosphates, and calcium phosphosilicates as well as allograft-derived materials and xenograft-derived materials such as collagen-based matrices and demineralized bone matrices. | 12-31-2015 |
| 20160015836 | Water-Equivalent Phantom - A composition for use in radiology includes glass micro bubbles, Araldite, Jeffamine, magnesium oxide, and polyethylene. Another composition or use in radiology may include glass micro bubbles, an epoxy, acrylic, or polyurethane, and polyethylene. This composition may result in an elemental composition including carbon, oxygen, hydrogen, nitrogen, calcium, and magnesium. A composition for use in radiology may include glass micro bubbles, araldite, jeffamine, calcium carbonate, magnesium oxide, polyethylene, and a pigment and the composition includes an elemental composition including carbon, oxygen, hydrogen, nitrogen, calcium, silicon, and magnesium. | 01-21-2016 |
| 20160015856 | SETTING OF HARDENABLE BONE SUBSTITUTE - The invention relates to hardenable ceramic bone substitute compositions having improved setting, powders for such compositions and methods for their manufacture and use in medical treatment. More specifically the invention relates to hardenable bone substitute powder and hardenable bone substitute paste with improved setting properties, comprising calcium sulfate and heat-treated hydroxyapatite (passivated HA), which bone substitute is suitable for treatment of disorders of supportive tissue such as bone loss, bone fracture, bone trauma and osteomyelitis. | 01-21-2016 |
| 20160074433 | TREATING AGENT AND TREATING METHOD FOR THE EXAMINATION OR OPERATION OF THE LARGE INTESTINE - A treating agent for the examination or operation of the large intestine which has high examination precision or facilitates an operation and can be administered with a small amount of water. The treating agent for the examination or operation of the large intestine contains magnesium oxide particles and is used to be orally administered before an examination or operation. | 03-17-2016 |
| 20160074448 | HERPES SIMPLEX VIRUS (HSV) WITH MODIFIED TROPISM, USES AND PROCESS OF PREPARATION THEREOF - A modified Herpes Simplex Virus (HSV), which has a portion of gD (glycoprotein D) of the glycoproteic envelope deleted and a heterologous single chain antibody inserted in place of such deleted portion; the modified HSV is capable of infecting cells through receptor HER2/ErbB2 but not through receptors HVEM/HveA and nectin1/HveC; uses of the modified HSV and a process of the preparation thereof are also disclosed. | 03-17-2016 |
| 20160082134 | Nanoparticle Photoacoustic Imaging Agents - The invention described herein relates to colloidal particles useful for photoacoustic imaging. The particles comprise a photoacoustic imaging agent with an absorbance maximum or plateau in the range of wavelengths 700-1100 nm. The imaging agent also displays low optical absorbance at some wavelength in the range 700-1100 nm. This combination of high and low optical absorbance enables background subtraction in photoacoustic imaging applications. The imaging agent is an organic compound having low aqueous solubility so that it is stably encapsulated in the hydrophobic core of the particle. The particle is stabilized by a polymeric surface coating, and the polymeric stabilizing layer on the surface of the particle may contain targeting ligands for targeted diagnostics or therapeutic delivery. The particle core may also contain therapeutic agents or other imaging agents. | 03-24-2016 |
| 20160090425 | ANTI-COMPLEMENT FACTOR C1S ANTIBODIES AND USES THEREOF - The present invention relates generally to the generation and characterization of neutralizing anti-C1s monoclonal antibodies. The invention further relates to the use of such anti-C1s antibodies in the detection of complement factors of the classical complement activation pathway, such as C1s. Additionally, the antibodies of this disclosure are useful for the diagnosis and treatment of disorders associated with an increased activation of the classical complement pathway, in particular autoimmune disorders and neurodegenerative diseases, including neurodegenerative diseases with synapse loss, such as Alzheimer's Disease. Methods of treatment of autoimmune and neurodegenerative diseases are also provided. | 03-31-2016 |
| 20160193366 | SILICONE-BASED ENTERIC CT CONTRAST MATERIAL | 07-07-2016 |
| 20160199508 | ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | 07-14-2016 |
